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Objectives This study investigated whether cytokine enhancement of a biodegradable patch could restore cardiac function
after surgical ventricular restoration (SVR) even when seeded with cells from old donors.
Background SVR can partially restore heart size and improve function late after an extensive anterior myocardial infarction.
However, 2 limitations include the stiff synthetic patch used and the limited healing of the infarct scar in aged
patients.
Methods We covalently immobilized 2 proangiogenic cytokines (vascular endothelial growth factor and basic fibroblast growth
factor) onto porous collagen scaffolds. We seeded human mesenchymal stromal cells from young (50.0  8.0 years,
N  4) or old (74.5  7.4 years, N  4) donors into the scaffolds, with or without growth factors. The patches were
characterized and used for SVR in a rat model of myocardial infarction. Cardiac function was assessed.
Results In vitro results showed that cells from old donors grew slower in the scaffolds. However, the presence of cyto-
kines modulated the aging-related p16 gene and enhanced cell proliferation, converting the old cell phenotype
to a young phenotype. In vivo studies showed that 28 days after SVR, patches seeded with cells from old donors
did not induce functional recovery as well as patches seeded with young cells. However, cytokine-enhanced
patches seeded with old cells exhibited preserved patch area, prolonged cell survival, and augmented angiogen-
esis, and rats implanted with these patches had better cardiac function. The patch became an elastic tissue,
and the old cells were rejuvenated.
Conclusions This sustained-release, cytokine-conjugated system provides a promising platform for engineering myocardial
tissue for aged patients with heart failure. (J Am Coll Cardiol 2012;60:2237–49) © 2012 by the American College
of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.08.985Heart failure continues to be an important cause of death
and disability from cardiovascular disease (1). Patients who
have had an extensive myocardial infarction (MI) are at risk
of heart failure because of adverse ventricular remodeling.
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accepted August 6, 2012.Surgical ventricular restoration (SVR) can normalize the
size and shape of the ventricle and improve heart function
(2). However, the STICH (Surgical Treatment for Ischemic
Heart Failure) trial demonstrated that SVR and coronary
artery bypass grafting (CABG) restored ventricular volumes
but did not improve symptoms, exercise ability, or global
ventricular function compared with CABG alone (3). Two
potential reasons for the limited improvement observed
See page 2250
with SVR include the use of a stiff, synthetic patch, which
renders the infarct scar and adjacent border zone fibrotic
and nonelastic, and the advanced age of the patients
undergoing the procedure, which renders them unable to
adequately heal the repaired region and maintain the re-
stored ventricular function because of dysfunctional stem
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Cytokines Enhance Cell-Seeded Patch for SVR November 20/27, 2012:2237–49cells. Therefore, we investigated
a new intervention intended to
restore elasticity to the ventricu-
lar repair and rejuvenate the aged
phenotype.
Pre-clinical studies demon-
strated that SVR was more effec-
tive than medical therapy after an
extensive MI (4–6); however,
the use of stiff, synthetic patches
was associated with recurrent
ventricular dilation (4–7). Initial
studies with biodegradable scaf-
folds demonstrated that they in-
duced cellular recruitment and
engraftment, resulting in viable
tissue after the patch dissolved
(8). Seeding the biodegradable
patches with cells increased the
thickness of the construct com-
pared with nonseeded patches by
increasing cellular infiltration and
engraftment (9,10). However,
thicker patches have limited perfu-
sion and the cells in the center die,
limiting the benefit of these grafts.
Immobilization of cytokines
within the biodegradable biomate-
rial has been reported to provide
sustained cytokine release to in-
duce angiogenesis, improve cell
survival, and enhance cell recruit-
ment (11,12). We previously de-
veloped a method to covalently
immobilize angiogenic cytokines to a collagen scaffold (11,12),
resulting in their sustained release and producing an angiogenic
effect in both the biomaterial and the surrounding tissue. This
platform, consisting of conjugated cytokines but no cells, was
successfully used to repair defects of the right ventricular
outflow tract in a rat model (12).
Preliminary studies in children demonstrated that cell-
seeded biodegradable vascular patches resulted in the
formation of viable tissue after the biomaterial dissolved
(13). However, this approach may be difficult in older
patients with extensive coronary artery disease. We and
others demonstrated that bone marrow cells from older
individuals do not restore heart function as well as cells
from younger individuals and that older recipients of cell
therapy do not respond as well as younger recipients
(14,15). In the current study, we created a cytokine-
enhanced cardiac patch by immobilizing vascular endo-
thelial growth factor (VEGF) and basic fibroblast growth
factor (bFGF) onto a collagen scaffold and seeding it with
human mesenchymal stromal cells (hMSCs) isolated
from younger or older patients with cardiac disease. We
Abbreviations
and Acronyms
-SMA  alpha smooth
muscle actin
bFGF  basic fibroblast
growth factor
BrdU  bromodeoxyuridine
CABG  coronary artery
bypass grafting
ELISA  enzyme-linked
immunosorbent assay
hMSCs  human
mesenchymal stromal cells
LV  left ventricular
LVIDd  left ventricular
internal diastolic dimension
LVIDs  left ventricular
internal systolic dimension
MI  myocardial infarction
PCR  polymerase chain
reaction
p16  CDKN2A, cyclin-
dependent kinase inhibitor
2A
RGN  regucalcin
(senescence marker
protein-30)
SVR  surgical ventricular
restoration
VEGF  vascular
endothelial growth factor
vWF-FVIII  von Willebrand
factor–factor VIIIevaluated the potential of this cytokine-enhanced, cell- Sseeded patch to improve recovery of ventricular function
after SVR.
Methods
Please refer to the Online Methods section for further
details.
Bone marrow collection. The collection of human samples
was approved by the Research Ethics Board of University
Health Network. Each patient provided informed consent.
Bone marrow aspirates were obtained from the sternum of
patients undergoing CABG at Toronto General Hospital.
“Young” hMSCs were isolated from patients age 57 years
(50.0  8.0 years, N  4); “old” hMSCs were isolated from
patients age 66 years (74.5  7.4 years, N  4).
Preparation of the collagen scaffolds. The collagen scaf-
folds were prepared and immobilized with cytokines as
previously described (11,12). Four groups of scaffolds were
tested with and without growth factors: fresh (scaffolds right
after preparation), blank (scaffolds incubated in media for 3
days), young (scaffolds seeded with young hMSCs and
incubated in media for 3 days), and old (scaffolds seeded
with old hMSCs and incubated in media for 3 days). The
tensile strength of the scaffolds was tested with the Elec-
troForce 5200 BioDynamic Test Instrument (Bose, Eden
Prairie, Minnesota) using the 22 N load sensor, and their
structure was examined by scanning electron microscopy.
Immobilized and free VEGF and bFGF levels in the
phosphate-buffered saline supernatant and scaffolds were
quantified with enzyme-linked immunosorbent assay
(ELISA).
Bone marrow cell–engineered scaffolds. Isolated hMSC
seeding was performed as previously described (11,12). Cell
numbers in the scaffolds were evaluated with the MTT assay
after 2 and 4 days of culture. Proliferating cells were labeled
with bromodeoxyuridine (BrdU), and after culturing for
48 h, the scaffolds were stained with BrdU antibody. The
BrdU-positive cells in the scaffolds were counted in 5
randomly selected high-power (20) fields and expressed as
a percentage. Staining with antibodies against alpha-
smooth muscle actin (-SMA) and connexin 43 was per-
ormed after 4 days of culture. The scaffolds were evaluated
n 5 randomly selected high-power (20) fields, and the
umber of positively stained cells was counted and expressed
s a percentage. The mRNA profiles of collagen type I and
II, cyclin-dependent kinase inhibitor 2A (CDKN2A or
16), and regucalcin (RGN) were assessed with real-time
olymerase chain reaction (PCR) after 4 days of culture.
xperimental animals. All animal procedures were per-
ormed in accordance with the Guide for the Care and Use
f Laboratory Animals (National Institutes of Health,
evised 1996) and approved by the Animal Care Committee
f University Health Network. To avoid immune rejection,
ll rats were given 5 mg/kg cyclosporine A (Novartis, Basel,
witzerland) intraperitoneally each day from 3 days before
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November 20/27, 2012:2237–49 Cytokines Enhance Cell-Seeded Patch for SVRto 28 days after patch implantation. A transmural MI was
generated in adult rats, and 2 weeks later, echocardiography
was used to screen the rats on the basis of infarct size
(Online Fig. S1). Only those animals with an akinetic
infarct area greater than 25% but less than 35% of the left
ventricular (LV) free wall were randomly assigned to one of
the following groups and underwent SVR: Control 
collagen patch; GF  collagen patch covalently immobi-
lized with growth factors; Old collagen patch seeded with
old hMSCs; Young  collagen patch seeded with young
hMSCs; Old  GF  collagen patch covalently immobi-
lized with growth factors and seeded with old hMSCs;
YoungGF collagen patch covalently immobilized with
growth factors and seeded with young hMSCs.
Patch implantation was performed 14 days after coronary
ligation, as previously described (9,16). LV function was
evaluated by echocardiography before MI (pre-ligation
baseline), before patch implantation (day 0), and 7, 14, and
28 days afterward. Assessment of patch morphology and cell
survival and vascular density was performed 28 days after
patch implantation. Identification of the cells in the patch
was performed by immunostaining. Details are provided in
the Online Methods section.
Statistical analysis. Statistical analysis was performed with
GraphPad Prism v4. All data are expressed as mean  SD.
Comparisons among groups were made with 1-way or
2-way analysis of variance or analysis of covariance. If the F
test was significant, pairwise tests of individual group means
were carried out using the Newman-Keuls post-test, Bon-
ferroni post-test, or Duncan’s multiple range test. A p value
0.05 was considered statistically significant.
Results
Scaffold characterization. We first characterized the scaf-
folds to ensure that cytokine immobilization did not ad-
versely affect the stiffness, strength, or porosity of the
scaffolds and, therefore, their usefulness for SVR. Stress–strain
curves demonstrated that cytokine-free and -enhanced scaffolds
exhibited similar behaviors during the breaking process
(Fig. 1A). Young’s modulus, a measure of stiffness, did not
differ with the addition of growth factors to the scaffold
(Fig. 1B). Ultimate tensile strength, the maximum stress a
material can withstand while being stretched, was lower in
cytokine-enhanced scaffolds than in cytokine-free scaffolds,
with the exception of the Old group (Fig. 1C). However,
the ultimate tensile strength was calculated at the final
breaking point, at approximately 300% strain. Because
this strain is not applicable in vivo, the Young’s modulus
is more suitable for characterizing the mechanical prop-
erty of the scaffolds for our application. Scanning electron
microscopy showed no significant differences in the porosity
or pore structures of the scaffolds with or without cytokines
(Fig. 1D).
To ensure covalent immobilization of the growth factors
to the collagen scaffolds (and not just physical attachment),we used ELISA to determine the immobilization efficien-
cies for VEGF and bFGF, which were 42% and 24%,
respectively, and the physical bonding efficiencies, which
were 2% and 5% (Fig. 1E), demonstrating that both
cytokines were chemically immobilized to the scaffolds. The
scaffolds were prepared to provide a slow release of cytokines
over time after SVR. The release study, based on ELISA,
demonstrated that the amount of cytokine released from the
scaffolds over 4 weeks was small, but the release rates were
similar for VEGF and bFGF (Fig. 1F). A significant
amount of each cytokine remained in the scaffolds after 28
days (Fig. 1G).
hMSC number, proliferation, and differentiation in scaf-
folds in vitro. Because cell engraftment within the scaffold
increases the thickness of the patch and results in a viable
tissue after the patch dissolves, we evaluated hMSC prolif-
eration within the scaffold. The MTT assay demonstrated
that the number of hMSCs increased within both the
cytokine-free and -enhanced scaffolds, whether from young
or old donors (Fig. 2A). As expected, the old hMSCs
seeded in cytokine-free scaffolds had the least number of
cells at both days 2 and 4 after seeding. Culturing the old
hMSCs in cytokine-enhanced scaffolds significantly in-
creased cell numbers to the levels seen with young cells.
BrdU staining demonstrated fewer proliferating cells in
cytokine-free patches seeded with old hMSCS than with
young cells (Figs. 2B and 2C). Culturing old hMSCs in
cytokine-enhanced scaffolds significantly increased the
number of proliferating cells to a level similar to that of
young hMSCs.
We also assessed the effect of the cytokines on differen-
tiation of the hMSCs seeded in the scaffolds. As demon-
strated in Figure 3, cytokine stimulation produced different
responses in hMSCs from young and old donors. Real-time
PCR showed that the mRNA expression of collagen I and
III, characteristically secreted by fibroblasts, was signifi-
cantly greater in older cells, and cytokine enhancement
dramatically down-regulated this expression. In contrast,
mRNA expression of collagen I and III in younger cells
increased with cytokine stimulation (Figs. 3A and 3B). A
similar trend was observed with immunostaining for
-SMA and connexin 43 (Figs. 3C and 3D).
Cytokine-enhanced scaffolds modulated aging-related
genes in old hMSCs in vitro. The advanced age of most
patients who require SVR after an extensive MI limits their
ability to adequately heal the repaired infarct region of the
heart because of dysfunctional stem cells, and the value of
cell implantation is restricted because of stem cell exhaus-
tion in older patients. Therefore, we were interested in the
specific effects of cytokine stimulation on aging-related
genes in old hMSCs. Both p16 and RGN are oncogenes
associated with human rejuvenation (17,18) and are con-
ventionally used to assess the degree of aging. Higher
expression of p16 suggests less capacity for cell rejuvenation,
whereas higher RGN expression suggests greater cell regen-
eration potential. We evaluated the mRNA expression level
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(A) Stress–strain curves for cytokine-free scaffolds (solid lines) and cytokine-enhanced scaffolds (dashed lines) showed similar tensile strength with or without cells.
(B, C) Young’s modulus was not significantly different between cytokine-free and -enhanced scaffolds. (C) Ultimate tensile strength was significantly lower in cytokine-enhanced
scaffolds in all groups but the Old group (**p  0.01). However, this measure was obtained outside of the physiological range of strain. Young’s modulus provides a better
estimate of the physical characteristics of the patch in vivo. (D) Scanning electron microscopy (100 and 500) revealed similar porosity in scaffolds with and without growth
factors. (E) Enzyme-linked immunosorbent assay (ELISA) demonstrated that both vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) (150 ng of
each added to the scaffolds) were immobilized on the scaffolds, with little in the supernatant. Scaffolds with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide HCl/N-
hydroxysulfosuccinimide treatment served to show physical bonding of the cytokines to the scaffolds (not covalent immobilization). (F) ELISA demonstrated that little VEGF or bFGF was
released from the scaffolds over 28 days. (G) After day 28, ELISA showed that substantial amounts of VEGF and bFGF remained in the scaffolds. n  3/group. bFGF  basic fibroblast
growth factor; EDC  1-ethyl-3-(3-dimethylaminopropyl) carbodiimide HCl; GF  growth factor; PBS  phosphate-buffered saline; VEGF  vascular endothelial growth factor.
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within the scaffolds for 4 days. The old cells seeded in the
cytokine-free scaffolds demonstrated the highest p16
mRNA expression among the groups. Old hMSCs seeded
in the cytokine-enhanced scaffolds showed p16 mRNA
expression levels similar to those of the young cells, with or
without cytokines (Fig. 4A). The mRNA expression of the
aging-induced p16 gene was inhibited by the conjugated
cytokines. RGN showed a similar, but opposite, pattern;
however, the effects of the cytokines did not reach statistical
significance (Fig. 4B). We further investigated p16 by
Western blot analysis, which confirmed the real-time PCR
result (Fig. 4C). Staining the MSCs for p16 showed nuclear
Figure 2 Number and Proliferation of hMSCs in Scaffolds in Vit
(A) The MTT assay showed that the number of cells increased in all scaff
donors. Cell numbers were greater with scaffolds containing immobilized cytok
cell number was found among the Young, Old  GF, and Young  GF scaffolds
modeoxyuridine (BrdU) staining for proliferating cells. Arrows indicate BrdU (
young, rather than old, cells were seeded into the cytokine-free scaffolds. The
scaffold seeded with old, but not young, cells. Nuclei stained blue with DAPI. *
growth factor.and perinuclear localization of the protein (Fig. 4D).Old hMSCs in cytokine-enhanced patches improved
cardiac function and patch morphology after SVR. Our
in vivo study in rats assessed repair of the LV defect after
infarct excision and SVR using patches with or without
cytokines and with or without cells. Coronary artery ligation
of the rat hearts resulted in significant LV dilation and
progressive ventricular dysfunction, as assessed by echocar-
diography (Fig. 5A). All echocardiographic parameters were
virtually indistinguishable among the animals at the time of
patch implantation (day 0) (Figs. 5B to 5F) because of the
pre-selection of animals with similar infarct sizes. Two
weeks after SVR, fractional shortening, fractional area
change, and ejection fraction in the Old group had de-
ver time but was greater with cells from young donors compared with old
nd the increase was greater with old cells than young cells. No difference in
2 and 4 days. (B) Representative micrographs (200 and 400) of bro-
) cells. (C) The percentage of BrdU cells was significantly greater when
er of BrdU cells was significantly greater when cytokines were added to the
.05, **p  0.01 vs. Old; n  4/group. BrdU  bromodeoxyuridine; GF ro
olds o
ines, a
after
purple
numb
p  0creased more than in the Young and Young  GF groups
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Cytokines Enhance Cell-Seeded Patch for SVR November 20/27, 2012:2237–49Figure 3 Differentiation of hMSCs in Scaffolds In Vitro
(A, B) Expression of collagen I and III mRNA was assessed by real-time polymerase chain reaction (PCR) to indicate the extent of fibroblast differentiation within the scaffolds.
Both collagen I and III gene expression were higher in scaffolds seeded with cells from old versus young donors. The addition of cytokines decreased expression in scaffolds
seeded with old cells and increased expression in scaffolds seeded with young cells. (C) Representative micrographs (200 and 400) of immunofluorescent staining for
alpha smooth muscle actin (-SMA) (red) and connexin 43 (red) to determine differentiation to smooth muscle cells and fibroblasts. (D) Quantification of the staining showed
that scaffolds seeded with old cells had a significantly higher percentage of -SMA cells than scaffolds seeded with young cells. Addition of cytokines decreased the number
of -SMA old cells, but increased the number of -SMA young cells. GAPDH used as a loading control. Nuclei stained blue with DAPI. *p  0.05, **p  0.01 vs. Old; n 
4/group. -SMA  alpha smooth muscle actin; GF  growth factor.
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November 20/27, 2012:2237–49 Cytokines Enhance Cell-Seeded Patch for SVR(Figs. 5B to 5D). At 28 days, the protective effect of the
sustained cytokine release was reflected in the significant
preservation of fractional shortening and ejection fraction in
the Old  GF group, which was similar to that in the
Young and Young  GF groups (Figs. 5B and 5D). The
eft ventricular internal diastolic dimension (LVIDd) and
eft ventricular internal systolic dimension (LVIDs) in the
ld group increased by day 14 and continued this trend to
ay 28 (Figs. 5E and 5F). The sustained cytokine release
esulted in smaller LVIDd and LVIDs in the Old  GF
roup. The Old group was not different than the Control
roup (blank patch) or GF group (patch with immobilized
ytokines) for any of the parameters.
Cardiac function also was assessed with a pressure-
olume catheter (Fig. 6A). In contrast to the Old group, the
oung group was associated with better pre-load recruitable
troke work and end-systolic pressure-volume relationship,
oad-independent indices of ventricular function (Figs. 6B
nd 6C). Likewise, the immobilized cytokines exerted
eneficial effects on the patches seeded with cells from old
onors. Ejection fraction and dP/dt max, load-dependent
ndices of systolic function, also showed significant im-
Figure 4 Rejuvenation of Old hMSCs in Cytokine-Enhanced Sca
(A) Real-time PCR demonstrated that cyclin-dependent kinase inhibitor 2A (CDKN2
with cells from old versus young donors. Cytokine enhancement decreased p16 ex
folds. (B) RGN mRNA expression was significantly lower in cytokine-free scaffolds
folds increased RGN expression in old cells, but not significantly. (C) Western blo
seeded with old cells, and cytokine enhancement decreased p16 expression in th
p16 (red). Nuclei stained blue with DAPI. Arrows indicate p16-positive cells. GAPD
Glyceraldehyde 3-phosphate dehydrogenase; GF  growth factor; RGN  regucalcirovement with cytokine enhancement of old donor cells,endering the Old  GF group similar to both the Young
nd Young  GF groups (Figs. 6D and 6E). This trend
also was observed for the indices of diastolic function
(Figs. 6F and 6G), although it was not significant.
Because ventricular dilation has been demonstrated to
recur after SVR, we were interested in the patch morphol-
ogy after repair. A thin, dilated patch indicates initiation of
the redilation of the repaired ventricle. Patch area increased
in all groups on day 28 compared with the area before
implantation (Figs. 7A and 7B). However, the dilatation of
the patch was most dramatic in the Old group. Cytokine
enhancement of the patches seeded with old cells pre-
vented patch dilation similar to the patches seeded with
young cells. Patch thickness was identical in all groups
early after implantation. Similar to patch area, at 28 days
after implantation, the patches were least thick in the Old
group (Figs. 7C and 7D). Cytokine enhancement of the
patches seeded with old cells produced a trend to increased
patch thickness, but the difference was not significant.
Old hMSCs in cytokine-enhanced patches increased cell
survival and vascular density after SVR. We demon-
In Vitro
16) mRNA expression was significantly greater in cytokine-free scaffolds seeded
ion in old cells to levels seen with young cells in cytokine-free or -enhanced scaf-
d with cells from old versus young donors. Cytokine enhancement of the scaf-
ed that p16 protein expression was significantly greater in cytokine-free scaffolds
ells. (D) Representative micrographs (600) of immunofluorescent staining for
d as a loading control. *p  0.05, **p  0.01 vs. Old; n  4/group. GAPDH 
escence marker protein-30).ffolds
A or p
press
seede
t show
e old c
H use
n (senstrated that cell proliferation occurred in the scaffolds in
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Cytokines Enhance Cell-Seeded Patch for SVR November 20/27, 2012:2237–49vitro; however, cell survival after patch implantation is
necessary for cell engraftment and the formation of viable
tissue after the biomaterial dissolves. Staining of heart
sections for human mitochondria showed that cell sur-
vival 28 days after patch implantation was significantly
lower in the patches seeded with hMSCs from old donors.
However, cytokine enhancement significantly increased old
cell survival, but not to the level achieved with young cells
Figure 5 Cardiac Function Assessed by Echocardiography 28 D
(A) Representative M-mode echocardiographic images after patch implantation. (B to
cally in all groups from ligation (day 14) to patch implantation (day 0) and continued
tional area change, and ejection fraction were lowest in the Old group but improved w
left ventricular internal systolic dimension (LVIDs) increased dramatically in all groups
Control, and GF groups. At 28 days, LVIDd and LVIDs in the Old group were significan
Old vs. Old  GF, **p  0.01 Old vs. Young, Young  GF, ##p  0.01 Old vs. Old 
8. GF  growth factor; LVIDd  left ventricular internal diastolic dimension; LVIDs  l(Figs. 8A and 8B).To identify which types of cells were present in the patch
area after SVR, we performed staining with antibodies
against CD45, von Willebrand factor–factor VIII (vWF-
FVIII), discoidin domain receptor 2, SMA, and sarcomeric
actinin. Co-staining for human mitochondria identified
transplanted cells (Online Fig. S2). Human mitochon-
drial negative cells within the patch area were mostly
positive for CD45 and vWF-FVIII. Therefore, many
fter Patch Implantation In Vivo
ctional shortening, fractional area change, and ejection fraction decreased dramati-
rease in the Old, Control, and GF groups. At 28 days, fractional shortening, frac-
kine enhancement. (E, F) Left ventricular internal diastolic dimension (LVIDd) and
gation (day 14) to patch implantation (day 0), and this trend continued in the Old,
ller with cytokine enhancement. *p  0.05 Old vs. Young, Young  GF, #p  0.05
ontrol n  8, GF n  8, Old n  5, Young n  8, Old  GF n  6, Young  GF n 
tricular internal systolic dimension.ays A
D) Fra
to dec
ith cyto
from li
tly sma
GF; C
eft venhost cells infiltrated the patch area and may be contrib-
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November 20/27, 2012:2237–49 Cytokines Enhance Cell-Seeded Patch for SVRuting to angiogenesis. Transplanted cells (positive for
human mitochondria) were mostly positive for SMA and
discoidin domain receptor 2, indicating that some of the
hMSCs may have been in the process of transdifferentiation
to myofibroblasts.
To evaluate the angiogenic effect of the immobilized
cytokines in both the patch and surrounding tissue, we
stained heart sections for vWF-FVIII and -SMA to
Figure 6 Cardiac Function Assessed by Pressure-Volume Cathe
(A) Representative pressure-volume loops in response to vena cava occlusion. (B
with 95% confidence limits (black dotted lines). For both these load-independent
cytokine enhancement (n  4/group). (D, E) The load-dependent indices ejection
(Old n  5, Young n  8, Old  GF n  6, Young  GF n  8). (F, G) Tau-w and
the Old  GF and Old groups. *p  0.05, **p  0.01 vs. Old; Old n  5, Youngidentify capillary structures and mature vessels, respectively.Vascular density was lowest in the Old group, but it
increased significantly with the addition of cytokines so that
the Old  GF group had vascular densities similar to those
of the Young and Young  GF groups (Figs. 8C and 8D).
Discussion
This study demonstrated what may have been intuitively
8 Days After Patch Implantation In Vivo
ad recruitable stroke work and (C) end-systolic pressure-volume relationship
, the Old group exhibited depressed function, which significantly improved with
n and dP/dt max were significantly greater in the Old  GF versus the Old group
min, indices of diastolic function, did not show a significant difference between
, Old  GF n  6, Young  GF n  8. GF  growth factor.ter 2
) Pre-lo
indices
fractio
dP/dt
n  8anticipated—that cardiac patches seeded with cells from old
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well as patches seeded with cells from young donors.
Previous studies have established the benefits of cytokine
enhancement of cell-seeded cardiac constructs to induce
angiogenesis and improve cell survival. This is the first study
to suggest that cytokine enhancement restored the prolifer-
ative capacity of bone marrow cells from old donors and
permitted the recovery of ventricular function as well as cells
from young donors. The initial clinical trial of cell-seeded
cardiac patches (13) is encouraging, and the addition of
immobilized cytokines may permit the application of this
technique to the patients most in need—elderly survivors of
Figure 7 Patch Morphology 28 Days After Implantation In Vivo
(A) Representative images of rat hearts show the outer border of the patches dep
nimetry. The patch area increased in all groups from the original size of 39 mm2 (
after implantation than that in the other groups. The addition of cytokines significa
with Masson’s trichrome. Arrows indicate patch thickness. (D) Patch thickness wa
cantly thinner than patches in the Young and Young  GF groups. Cytokine enhan
**p  0.01 vs. Old; Old n  5, Young n  8, Old  GF n  6, Young  GF n an extensive MI.A major limitation of cell-seeded cardiac patches has
been low cell survival and proliferation. To overcome this,
investigators have attempted to create an interior vasculature
within the biomaterial to facilitate metabolic exchange
between the implanted cells and the microenvironment
(19,20) or to pre-condition the cell-seeded patch in vitro to
improve oxygen delivery to the bioengineered tissue (21).
The most promising approach has been the delivery of
growth factors (22) or genes (23) to shorten the period
between implantation and vascularization of the matrices.
The development of functionally mature vasculature is a
dynamic process that requires multiple cytokines acting
y the yellow dotted line. (B) Patch area was quantified using computerized pla-
tted line) at the time of SVR. Patch area in the Old group was significantly larger
evented patch expansion. (C) Representative images of heart slices stained
ntified using computerized planimetry. The patches in the Old group were signifi-
t did not significantly increase patch thickness for old or young cells. *p  0.05,
growth factor.icted b
red do
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cemen
8. GF sequentially (23), and investigators have attempted to ex-
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cytokine delivery (12,16). VEGF has been documented to
Figure 8 Cell Survival and Vascular Formation 28 Days After P
(A) Representative micrographs (200 and 400) of heart slices stained for hum
increased the number of surviving cells in the patches. (C) Representative microg
(red) to identify capillaries. (D) Formation of both arterioles and capillaries was si
showed significantly greater vascular density, to levels similar to patches with you
Young n  8, Old  GF n  6, Young  GF n  8. -SMA  alpha smooth musclbe an important growth factor that produces irregular,hyperpermeable capillaries (23), and bFGF enhances mat-
uration of the developing blood vessel network by recruiting
Implantation in Vivo
tochondria (red) after patch implantation. (B) Cytokine enhancement significantly
(200) of immunostaining for -SMA (red) to identify arterioles and vWF-FVIII
ntly less in the Old group. Cytokine-enhanced patches seeded with old cells
s. Nuclei stained blue with DAPI. *p  0.05, **p  0.01 vs. Old; Old n  5,
; GF  growth factor; vWF-FVIII  von Wiilebrand factor-factor VIII.atch
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VEGF and bFGF can synergistically accelerate the func-
tional angiogenesis induced by cell therapy (27).
The biodegradable collagen patch used for SVR in this
series is similar to other synthetic scaffolds previously
reported for this purpose. The material used in the initial
clinical trial (13) induced more tissue formation than the
nonbiodegradable materials currently used for LV repair (8).
Alternative approaches include decellularized biomaterials
(28–30), which retain regenerative cytokines and have been
used for cardiac repair. Extensive investigations will be
required to determine the best approach to repair the heart
by tissue engineering. We have previously demonstrated
that cytokine-enhanced biodegradable scaffolds induced
greater tissue in-growth and improved recovery of ventric-
ular function when used for SVR than control biodegrad-
able biomaterials not enhanced with cytokines (12–16).
The major finding of the current study was the limited
benefit achieved with SVR using patches seeded with cells
from old donors and the restoration of that benefit with the
immobilization of cytokines within the biomaterial. The
primary in vitro difference between the young and old
hMSCs was cellular proliferation, and cytokine enhance-
ment increased proliferation of the old cells. To further
explore the possible mechanisms of cytokine enhancement
of old hMSCs, we assessed expression of the aging-related
p16 and RGN genes in the hMSCs and demonstrated a
relation between cytokine enhancement and gene expres-
sion. This may be the first report to demonstrate that
stimulation of aged hMSCs with exogenous VEGF and
bFGF reversed the aging phenotype by modulating aging-
related gene expression. These preliminary findings require
further investigation to fully elucidate the effects of cytokine
stimulation on aged hMSCs.
The improvement in functional recovery after SVR with
cytokine-enhanced patches seeded with old cells may have
been the result of the increased proliferation of the im-
planted cells and possibly stimulation of the cardiac-resident
progenitor cells in the infarct border zone. Young cells and
cytokine-stimulated old cells induced angiogenesis not only
in the patch but also in the peri-infarct region. The
increased angiogenesis enhanced survival of both the im-
planted cells and the host cells. Cell engraftment was
associated with the preservation of patch area, prevention of
adverse matrix remodeling, and avoidance of ventricular
thinning and dilation. We identified smaller patches seeded
with young cells and cytokine-enhanced old cells 4 weeks
after implantation. Of note, the preservation of patch area
did not compromise new vessel formation or cell survival. As
such, the improvement in cardiac function was likely due to the
combination of preserved ventricular geometry and improved
perfusion, as demonstrated in our previous investigation of
SVR (16). Indeed, in the current study, ejection fraction
correlated significantly with cell survival, patch thickness, and
vascular density (Online Fig. S3).Conclusions
Restoration of cardiac function was possible with a
cytokine-enhanced, tissue-engineered patch that rejuve-
nated aged cells. Covalent immobilization of 2 proangio-
genic cytokines, VEGF and bFGF, onto a collagen scaffold
enhanced cell proliferation in vitro and prolonged cell
survival and improved angiogenesis to restore ventricular
morphology and function in vivo. Of note, the improvement
was most obvious with patches seeded with cells from old
donors. This novel cytokine-conjugated, sustained-release
system provides a practical and promising platform for
cardiac repair in elderly survivors of an extensive MI, an
important advance in an increasingly aging society.
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For an expanded Methods section, and supplemental figures and table,
please see the online version of this article.
